Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line
Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...
Na minha lista:
Publicado no: | Anal Cell Pathol (Amst) |
---|---|
Main Authors: | , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Hindawi
2018
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/ https://ncbi.nlm.nih.gov/pubmed/30034996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|